CEL-SCI CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award
CEL-SCI CORPORATION (CVM) reported Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award of 0 shares for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward · last filed 2025-05-14
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2025-03-31 was 0.00 shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2024-12-31 was 0.00 shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2024-06-30 was 0.00 shares.
- CEL-SCI CORPORATION share-based compensation arrangement by share-based payment award, shares purchased for award for the quarter ending 2024-03-31 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award 9 month |
|---|---|---|---|
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | 0.00 shares 10-Q · filed 2025-05-14 | |
| 2024-12-31 | 0.00 shares 10-Q · filed 2025-02-14 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-14 | 0.00 shares derived: sum of 2 quarters · filed 2025-05-14 | 0.00 shares 10-Q · filed 2024-08-14 |
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-14 | 0.00 shares 10-Q · filed 2025-05-14 | |
| 2023-12-31 | 0.00 shares 10-Q · filed 2025-02-14 | ||
| 2023-06-30 | 0.00 shares 10-Q · filed 2024-08-14 | 0.00 shares derived: sum of 2 quarters · filed 2024-08-14 | 0.00 shares 10-Q · filed 2024-08-14 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-15 | 0.00 shares 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |